Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Research Institute to Distribute GeneBio s Proteomics Software

NEW YORK, Nov. 24 (GenomeWeb News) - GeneBio has signed a distribution deal for its mass spec protein-identification software with the Bioinformatics Institute for Global Good in Japan, the company said today.

 

Tokyo-based BiGG will start "an extensive distribution campaign" for GeneBio's Phenyx software in Japan, using its business relationships with Hitachi Software Engineering and Netwell, according to Geneva-based GeneBio.

 

BiGG, founded in 2002, focuses on protein research programs and has links both to academic institutions and commercial organizations. The agreement paves the way for the distribution of other GeneBio products in Japanthrough BiGG an its member companies, according to GeneBio.

 

GeneBio's Phenyx software was developed in collaboration with the Swiss Institute of Bioinformatics and includes a scoring system developed at GeneProt in Geneva. It allows users to identify and characterize proteins and peptides from mass-spectrometry data.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.